Scarica l'app Stockscreener
78.05
0.95%
-0.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$78.80
Aprire:
$78.26
Volume 24 ore:
3.71M
Relative Volume:
0.87
Capitalizzazione di mercato:
$44.46B
Reddito:
$5.54B
Utile/perdita netta:
$4.18B
Rapporto P/E:
11.15
EPS:
7
Flusso di cassa netto:
$623.10M
1 W Prestazione:
+1.64%
1M Prestazione:
+3.42%
6M Prestazione:
+6.31%
1 anno Prestazione:
-15.94%
Intervallo 1D:
$77.05
$78.39
Intervallo di 1 settimana:
$75.84
$78.90
Portata 52W:
$58.93
$92.88
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Confronta EW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
78.05 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
|
ABT
Abbott Laboratories
|
132.02 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.20 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
389.46 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.92 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Edwards Lifesciences’ PROGRESS Trial: A Game-Changer for Aortic Stenosis Treatment? - TipRanks
Edwards Lifesciences Launches MITRIS Valve Study in China: A Potential Market Game-Changer - TipRanks
Edwards Lifesciences’ PASCAL System: A Promising Solution for Tricuspid Regurgitation - TipRanks
Argus Initiates Edwards Lifesciences at Buy, $90 Price Target - MarketScreener
Edwards Lifesciences’ SAPIEN X4 Valve Study: A Potential Game-Changer in Heart Valve Treatment - TipRanks
Edwards Lifesciences’ Pivotal Trial: A Game Changer in Tricuspid Valve Repair? - TipRanks
Edwards Lifesciences stock rating maintained at Hold by Canaccord Genuity - Investing.com Canada
Edwards Lifesciences’ PROGRESS Trial: A Game Changer for Aortic Stenosis Treatment? - TipRanks
Earnings Preview: What To Expect From Edwards Lifesciences' Report - MSN
Edwards Lifesciences’ PASCAL System Trial: A Potential Game-Changer for Tricuspid Valve Repair - TipRanks
Edwards Lifesciences’ PASCAL System: A Key Study Update for Investors - TipRanks
Edwards Lifesciences’ PASCAL System: A Promising Trial in Heart Valve Repair - TipRanks
Edwards Lifesciences’ ALT-FLOW II Trial: A Potential Game-Changer in Heart Failure Treatment - TipRanks
Edwards Lifesciences Advances Heart Valve Innovation with Innovalve Study Update - TipRanks
Edwards Lifesciences’ MiCLASP Study: A Key Update for Investors - TipRanks
EDWARDS' EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM EARNS APPROVAL IN CANADA - BioSpace
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need to Know - MSN
Court sides with Cardiovalve in Edwards patent spat - MassDevice
Edwards Can't Get Fed. Circ. To Overrule PTAB Amendments - Law360
Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Is Edwards Lifesciences Stock Underperforming the Dow? - MSN
Is Edwards Lifesciences Stock Underperforming The Dow? - Barchart.com
Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan
DBS Bank Adjusts Price Target on Edwards Lifesciences to $78 From $72, Maintains Hold Rating - MarketScreener
Leerink Partnrs Has Positive Estimate for EW Q3 Earnings - Defense World
Leerink Partners Adjusts PT on Edwards Lifesciences to $83 From $77, Maintains Market Perform Rating - marketscreener.com
Health Care Slips as Sector Continues to Lag Market -- Health Care Roundup - marketscreener.com
Edwards Lifesciences stock rises following competitor’s exit - Investing.com
Edwards Lifesciences’ SWOT analysis: stock poised for growth amid market expansion - Investing.com
Edwards' data shows benefits of early intervention in aortic stenosis - BioWorld MedTech
Edwards’ study demonstrates value in early aortic stenosis intervention - Yahoo Finance
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock - Yahoo Finance
Assessing Edwards Lifesciences: Insights From 6 Financial Analysts - Benzinga
Edwards Lifesciences (EW) Receives Price Target Increase from Ci - GuruFocus
Edwards Lifesciences (EW) Receives Price Target Increase from Citigroup | EW Stock News - GuruFocus
Edwards highlights cost savings, improved outcomes with prompt intervention for aortic stenosis - MassDevice
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes - marketscreener.com
Citigroup Adjusts Price Target on Edwards Lifesciences to $95 From $84, Maintains Buy Rating - marketscreener.com
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | - GuruFocus
Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stoc - GuruFocus
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | EW Stock News - GuruFocus
Citi adds Edwards Lifesciences stock as Top Pick, drops Insulet - Investing.com
Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind - insights.citeline.com
Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone” - Insider Monkey
Edwards Gets FDA Approval for its Next-Generation TAVR Device - Medical Product Outsourcing
Should Edwards Lifesciences Stock Remain in Your Portfolio Now? - Yahoo Finance
Movers & Shakers: Grant Thornton, United Drug, Edwards Lifesciences, Fine Grain, Viatel, Kepak, EU Commission - Business Post
Edwards Loses Heart Valve Patent In Latest Clash With Meril - Law360
Edwards Lifesciences Completes Sale of Critical Care - Quantisnow
Do Wall Street Analysts Like Edwards Lifesciences Stock? - Nasdaq
Edwards Lifesciences (EW) Sees Price Target Increase Amid Regula - GuruFocus
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Edwards Lifesciences Corp Azioni (EW) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Wood Larry L | Global President TAVR & Surg |
Jun 16 '25 |
Sale |
75.23 |
8,950 |
673,268 |
206,900 |
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):